InsiderTrades

Form 4 for ENTA ENANTA PHARMACEUTICALS INC

Accepted 2024-02-14 00:00:00 ET · period of report 2024-02-12 · accession 0001062993-24-003223 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2024-02-14 2024-02-12 ENTA Luly Jay R. Pres, CEO, Dir F - Tax $12.41 -1,584 810.6K -0.2% -$19.7K
2024-02-14 2024-02-12 ENTA Luly Jay R. Pres, CEO, Dir A - Grant $0.00 +5,400 812.2K +0.7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-12 F D 1,584 $12.41 810,609 D — — (F2) Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU awards.
2 Common Common Stock 2024-02-12 A A 5,400 $0.00 812,193 D — — (F1) Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2022-2023 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2024.